Clinical trials
Active, not recruiting Urinary Bladder Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
142 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 8 |
| 2018 | 11 |
| 2019 | 16 |
| 2020 | 16 |
| 2021 | 19 |
| 2022 | 16 |
| 2023 | 13 |
| 2024 | 14 |
| 2025 | 7 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 142 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 13 |
| Memorial Sloan Kettering Cancer Center | 9 |
| M.D. Anderson Cancer Center | 8 |
| AstraZeneca | 5 |
| Jonsson Comprehensive Cancer Center | 4 |
| Merck Sharp & Dohme LLC | 4 |
| BicycleTx Limited | 3 |
| Janssen Research & Development, LLC | 3 |
| Cedars-Sinai Medical Center | 2 |
| Fox Chase Cancer Center | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urinary Bladder Neoplasms | 142 |
| Carcinoma, Transitional Cell | 35 |
| Ovarian Neoplasms | 19 |
| Prostatic Neoplasms | 17 |
| Non-Muscle Invasive Bladder Neoplasms | 16 |
| Carcinoma, Non-Small-Cell Lung | 12 |
| Carcinoma, Renal Cell | 12 |
| Lung Neoplasms | 12 |
| Stomach Neoplasms | 12 |
| Triple Negative Breast Neoplasms | 12 |
Trials
Showing 26 to 50 of 142. Each trial links to its page on Pharma Observatory.
42 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.